Speaker Programs Sample Clauses
Speaker Programs. Merit shall establish and implement:
a. A process to require all speakers to complete training and enter written agreements that describe the scope of work to be performed, the speaker fees to be paid, and compliance obligations for the speakers (including requirements regarding the use of Merit approved materials).
b. A centralized, electronic system to initiate and track all speaker programs that includes controls designed to ensure that speaker programs are used for legitimate and lawful purposes in accordance with all applicable Federal health care program and FDA requirements.
c. A process to ensure speakers are paid according to a centrally managed, pre-set rate structure determined based on an independent fair-market value analysis.
d. A comprehensive list of speaker program attendees through its centralized system. In addition, Merit shall use its centralized system to handle all logistics and spending associated with speaker programs, including the tracking and review of the aggregate amount (including speaker fees, travel, and other expenses) paid to each speaker in connection with speaker programs.
e. A requirement for certifications by sales representatives or other Merit personnel that a speaker program complied with Merit requirements, or in the event of non-compliance, Merit shall require the identification of the policy violation and ensure appropriate follow up activity to address the violation.
Speaker Programs. As between the Parties, Kura shall have the sole right to engage HCPs for speaking services and implement speaker programs related to the Ziftomenib Product in the U.S. Territory in accordance with the U.S. Territory Commercialization Plan and Budget, provided that KKUS may engage HCPs for speaking services and implement speaker programs related to the Ziftomenib Product in the U.S. Territory in accordance with the U.S. Territory Commercialization Plan and Budget upon Kura’s prior written consent [***]. Kura will consult with KKUS with respect to its engagement of HCPs for speaking services and implementation of speaker programs for the Ziftomenib Product, and Kura will consider KKUS’s timely comments in good faith. Kura shall ensure KKUS is given reasonable advance notice of speaker program events and KKUS shall have the right to attend and to invite HCPs to attend speaker program events. For clarity, if Kura approves KKUS’s right to engage HCPs for speaking services and implement speaker programs related to the Ziftomenib Product in the U.S. Territory, then (a) [***], (b) [***] and (c) [***].
Speaker Programs. (a) Cubist, []* implement promotional speaker programs concerning the Product (including through a Third Party vendor as set forth below in this Section 3.3(a)) (“Cubist Speaker Programs”). The Cubist Speaker Programs may be directed to []*. At least one Representative shall attend each Cubist Speaker Program. Notwithstanding anything contained herein, the parties acknowledge and agree that Cubist shall have the right to implement Cubist Speaker Programs through a Third Party vendor that is reasonably acceptable to AstraZeneca. []*.
(b) The development, approval and implementation of the Cubist Speaker Programs, including the content used therein, shall be subject to the procedures set forth in Exhibit D. Notwithstanding anything in Exhibit D to the contrary, Cubist shall not use any *Confidential Treatment Requested. Omitted portions filed separately with the Commission. written, printed, electronic or graphic material to Promote the Product during a Speaker Program other than (i) the Product Labels and Inserts, and (ii) Promotional Materials (including reminder items and slide decks) (as provided by AstraZeneca or its Affiliates, or, if applicable, reproduced by Cubist in accordance with this Agreement).
(c) For clarity, the Cubist Speaker Programs, and any activities in support thereof, shall not constitute Details for purposes of Section 3.1(a).
(d) AstraZeneca shall ensure that all slide decks provided by AstraZeneca or its Affiliates to Cubist for use in the Speaker Programs comply with Applicable Law and AstraZeneca’s applicable business policies (to the extent consistent with Applicable Law and this Agreement).